Nutrition and Clinical Services Division, International Centre for Diarrhoeal Disease Research,Bangladesh (icddr,b), Dhaka, Bangladesh.
Department of Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
BMJ Open. 2023 Apr 12;13(4):e068660. doi: 10.1136/bmjopen-2022-068660.
Diarrhoea is one of the leading causes of under-5 childhood mortality and accounts for 8% of 5.4 million global under-5 deaths. In severely malnourished children, diarrhoea progresses to shock, where the risk of mortality is even higher. At icddr,b Dhaka Hospital, the fatality rate is as high as 69% in children with severe malnutrition and fluid refractory septic shock. To date, no study has evaluated systematically the effects of inotrope or vasopressor or blood transfusion in children with dehydrating diarrhoea (eg, in cholera) and severe acute malnutrition (SAM) or severe underweight who are in shock and unresponsive to WHO-recommended fluid therapy. To reduce the mortality of severely malnourished children presenting with diarrhoea and fluid refractory shock, we aim to compare the efficacy of blood transfusion, dopamine and epinephrine in fluid refractory shock in children who do not respond to WHO-recommended fluid resuscitation.
In this randomised, three-arm, controlled, non-masked clinical trial in children 1-59 months old with SAM or severe underweight and fluid refractory shock, we will compare the efficacy of dopamine or epinephrine administration versus blood transfusion in children who failed to respond to WHO-recommended fluid resuscitation. The primary outcome variable is the case fatality rate. The effect of the intervention will be assessed by performing an intention-to-treat analysis. Recruitment and data collection began in July 2021 and are now ongoing. Results are expected by May 2023.
This study has been approved by the icddr,b Institutional Review Board. We adhere to the 'Declaration of Helsinki' (2000), guidelines for Good Clinical Practice. Before enrolment, we collect signed informed consent from the parents or caregivers of the children. We will publish the results in a peer-reviewed journal and will arrange a dissemination seminar.
NCT04750070.
腹泻是导致 5 岁以下儿童死亡的主要原因之一,占全球 540 万 5 岁以下儿童死亡人数的 8%。在严重营养不良的儿童中,腹泻会发展为休克,死亡率更高。在 icddr,b 达卡医院,严重营养不良且对液体无反应的感染性休克儿童的死亡率高达 69%。迄今为止,尚无研究系统评估在脱水性腹泻(如霍乱)和严重急性营养不良(SAM)或严重消瘦且对世卫组织推荐的液体疗法无反应的休克儿童中使用儿茶酚胺或血管加压素或输血的效果。为降低腹泻和液体无反应性休克的严重营养不良儿童的死亡率,我们旨在比较输血、多巴胺和肾上腺素在对世卫组织推荐的液体复苏无反应的儿童中治疗液体无反应性休克的疗效。
在这项针对 1-59 个月大的 SAM 或严重消瘦且液体无反应性休克儿童的随机、三臂、对照、非盲临床试验中,我们将比较对世卫组织推荐的液体复苏无反应的儿童使用多巴胺或肾上腺素与输血的疗效。主要结局变量是病死率。将通过意向治疗分析评估干预效果。招募和数据收集于 2021 年 7 月开始,目前正在进行。结果预计于 2023 年 5 月公布。
这项研究已获得 icddr,b 机构审查委员会的批准。我们遵守“赫尔辛基宣言”(2000 年)和良好临床实践指南。在入组前,我们会从儿童的父母或监护人那里收集签署的知情同意书。我们将在同行评议的期刊上发表研究结果,并安排传播研讨会。
NCT04750070。